Although KRAS mutations are present in the majority of pancreatic cancers, the nature of the KRAS mutation, the presence of additional mutations with lower prevalence and the molecular subtype all have the potential to alter dependency on cell signalling pathways. The gene discussed is KRAS; the disease is pancreatic neoplasm.